People with inflammatory bowel disease are at higher risk for Parkinson’s—but not if they take anti-inflammatory medication.
Thirty-five reviews cover two decades of Alzheimer’s research.
Three genome-wide association studies, including the largest-ever thanks to UK Biobank, reveal 13 new AD risk loci. They implicate APP processing in LOAD, and further highlight inflammation and lipid metabolism.
Transportins, methylation, and RNA all regulate LLPS and the behavior of pathogenic RNA-binding proteins.
At AAT-AD/PD, scientists said an α-synuclein PET tracer is headed into trials. And marmosets model PD behaviors better than rodents. (Spoiler alert: They kick their partners while they sleep.)
Systemic inflammation can alter the epigenome of microglia, dictating whether the cells clean up Aβ pathology, or exacerbate it.
Massive meta-analysis finds no link with AD or PD.
Volunteers kept awake all night retained more florbetaben in their hippocampi and thalami in morning-after PET scan.
In animal models, a PD risk gene revs up the immune system to fight infections, while probiotic bacteria slow α-synuclein aggregation.
Researchers at AAT-AD/PD discussed investigational PD treatments that aim to modify disease by hitting genetic risk factors.
For the first time, NIA-AA proposal bases diagnosis in living people solely on biomarkers for plaques and tangles.
An infrared spectral signature of amyloid β-sheets predicted AD conversion years before diagnosis.
A study reported that new neurons continue to sprout from the human hippocampus well into the golden years, while another claims they all but disappear after childhood.
A widely popularized finding of shrinking dementia rates is entirely due to less vascular dementia, and is in fact concealing a rise in AD and PD, according to a provocative talk at AAT-AD/PD.
Maybe it’s not hyperexcitability, after all. Correlating electrical activity with muscle strength, scientists conclude that motor neurons become hypoexcitable just before degenerating.